Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2022-11-11 Regulatory Filings
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Quarterly Filings by the Interim CFO of Avicanna Inc. It certifies the review and fair presentation of quarterly financial statements and MD&A for the three-month period ended September 30, 2022. The document is primarily an officer certification regarding the quarterly filings, internal controls, and disclosure controls. It does not contain the actual financial statements or substantive financial data but rather attests to their accuracy and completeness. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the quarterly report itself (IR). The document length is about 5037 characters, consistent with a certification letter rather than a full quarterly report.
2022-11-11 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F1 Certification of Quarterly Filings by the CEO of Avicanna Inc. It certifies the review and fair presentation of quarterly financial statements and MD&A for the three-month period ended September 30, 2022. The document is primarily an officer certification attesting to the accuracy and completeness of the quarterly filings and the effectiveness of disclosure controls and internal controls over financial reporting. It does not contain the actual financial statements or substantive financial data but serves as a formal attestation as required by securities regulations. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the quarterly report itself (IR). The document length is about 5007 characters, consistent with a certification letter rather than a full report.
2022-11-11 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is a Management's Discussion and Analysis (MD&A) for Avicanna Inc. It contains detailed explanations of business overview, financial results, operations, liquidity, and critical accounting policies. It references the condensed consolidated interim financial statements for the three and nine months ended September 30, 2022, and is prepared as of November 11, 2022. The content includes forward-looking statements, business segments, market opportunities, and Q3 2022 financial highlights. This matches the characteristics of a Management Reports (MDA) filing, which provides management's detailed explanation of financial results, business trends, and outlook. The document is not a full Annual Report (10-K), nor is it a short announcement or certification. It contains substantive financial data and analysis for an interim period, but the primary focus is on management discussion rather than the full financial statements themselves, which aligns with MDA rather than IR. Therefore, the correct classification is MDA with high confidence.
2022-11-11 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Avicanna Inc. Condensed Consolidated Interim Financial Statements (Unaudited) For the Three and Nine Months Ended September 30, 2022, and 2021'. It contains detailed financial statements including statements of financial position, operations, changes in equity, cash flows, and notes. The period covered is an interim period (three and nine months ended September 30, 2022 and 2021). The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with an Interim / Quarterly Report as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). 9M 2022
2022-11-11 English
News release - English.pdf
Regulatory Filings
2022-11-11 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the extension of a term loan agreement by Avicanna Inc. It details the terms of the loan extension, including the new maturity date, interest payments, and principal repayments. There is no financial statement, comprehensive financial data, or detailed analysis of financial results. The content focuses on financing activity, specifically the update on the company's debt arrangement. It is not an annual or interim report, audit report, earnings release, or any other detailed financial report. The document fits the category of Capital/Financing Update (CAP) as it provides an update on the company's financing activities related to its term loan.
2022-10-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.